- Citius Oncology, Inc. (CTOR) has finalized a U.S. distribution agreement with **McKesson Corporation** (MCK) for its FDA-approved immunotherapy, **LYMPHIR**.  **[1851484_20251020NY00910:0]** 
- This agreement completes Citius Oncology's core U.S. distribution network, securing broad access for LYMPHIR's planned commercial launch in the **fourth quarter of 2025**.  **[1851484_20251020NY00910:0]** 
- LYMPHIR, approved in **August 2024** for relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL), targets an initial market estimated to exceed **$400 million**.  **[1851484_20251020NY00910:0]** **[1851484_20251020NY00910:3]**

Citius Oncology Signs U.S. Distribution Agreement with McKesson for LYMPHIR

- **Citius Oncology (CTOR)** has finalized an exclusive agreement with **EVERSANA** to support the anticipated **Q4 2025 U.S. commercialization of LYMPHIR™**.  **[1851484_20251016NY98763:0]** 
- **LYMPHIR™**, an **FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL)**, received its approval in **August 2024**.  **[1851484_20251016NY98763:0]** **[1851484_20251016NY98763:3]** 
- EVERSANA will serve as Citius Oncology's exclusive commercialization partner, providing integrated services including medical information, pharmacovigilance, and revenue cycle management.  **[1851484_20251016NY98763:0]** 
- The estimated initial market for LYMPHIR™ **exceeds $400 million** and is growing.  **[1851484_20251016NY98763:3]**

Citius Oncology Finalizes Exclusive Commercialization Agreement with EVERSANA for LYMPHIR Launch

- **Citius Oncology (CTOR)** has signed an exclusive distribution agreement with Integris Pharma S.A. to provide **LYMPHIR™** through Named Patient Programs in Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro, and North Macedonia.  **[1851484_20251007NY91922:0]** 
- This initiative expands international access for LYMPHIR, a **targeted immune therapy** for relapsed or refractory cutaneous T-cell lymphoma (CTCL) that received FDA approval in **August 2024**.  **[1851484_20251007NY91922:0]** **[1851484_20251007NY91922:1]** 
- The company is also actively discussing with other potential distribution partners in additional European Union member states, South America, and select Middle Eastern territories to further position LYMPHIR for global growth.  **[1851484_20251007NY91922:1]**

CITIUS ONCOLOGY (CTOR)